Key result
PDE1 emerges as a key cardiomyocyte regulator and potential therapeutic target in HF.
Design
Editorial
Authors
Loading...
PDE1 inhibition merits preclinical and early clinical exploration in heart failure; leaves open whether benefits will reach patients.
Highlights recent evidence establishing PDE1 as a key regulator of cardiomyocyte physiology and a potential therapeutic target for heart failure.
Leroy et al. (2018) conducted an editorial in Heart failure. PDE1 inhibitors was evaluated. PDE1 is confirmed as an important regulator of cardiomyocyte physiology and established as a potential therapeutic target for newly synthesized inhibitors to improve cardiac function in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: